Evidence map›Paper›PMID 40779752›Full record

Trial reportJMIR formative research2025

Development of a Sham Smartphone App for Opioid Use Disorder: Acceptability and Suitability Study.

Kierstyn S Gallegos, Jennifer S Potter, Van L King, Gregg Siegel, Leslie H Siegel, Elise N Marino

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in JMIR formative research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kierstyn S Gallegos *Be Well Institute on Substance Use and Related Disorders, University of Texas Health Science Center at San Antonio, 5109 Medical Drive, San Antonio, TX, 78229, United States, 1 210 450 3760.ORCID 0000-0003-3382-4455
Jennifer S Potter *Be Well Institute on Substance Use and Related Disorders, University of Texas Health Science Center at San Antonio, 5109 Medical Drive, San Antonio, TX, 78229, United States, 1 210 450 3760.ORCID 0000-0002-7250-4422
Van L King *Be Well Institute on Substance Use and Related Disorders, University of Texas Health Science Center at San Antonio, 5109 Medical Drive, San Antonio, TX, 78229, United States, 1 210 450 3760.ORCID 0000-0002-1557-8222
Gregg Siegel *Biomedical Development Corporation, San Antonio, TX, United States.ORCID 0000-0003-4483-3517
Leslie H Siegel *Biomedical Development Corporation, San Antonio, TX, United States.ORCID 0000-0002-5545-8989
Elise N Marino *Be Well Institute on Substance Use and Related Disorders, University of Texas Health Science Center at San Antonio, 5109 Medical Drive, San Antonio, TX, 78229, United States, 1 210 450 3760.ORCID 0009-0000-8190-9985

Funding

mHealth for Patient Self-Management of Opioid Use Disorder - Administrative SupplementR42DA054881 · NIDA · BIOMEDICAL DEVELOPMENT CORPORATION · PI POTTER, JENNIFER SHARPE · 2021 to 2023
$2.6M
NIDA NIH HHS R42 DA054881
6 · The paper itself

Abstract

Background: Despite having evidence-based medication for opioid use disorder (OUD), dropout is one of the most common issues noted with this treatment. Prescription digital therapeutics, which are app-based interventions prescribed by a health care professional, have the potential to increase adherence to medication for OUD and retention while overcoming treatment barriers, including provider capacity and patient access. Using a sham app as a control condition for a randomized clinical trial is an innovative method to establish the true efficacy of these apps. Objective: This study included the development and testing of a sham smartphone app for OUD. Methods: After the sham app was developed, participants were enrolled in a 4-week trial examining the use and suitability of the sham app as a control condition. Criteria for determining suitability included (1) participants believing the sham app is an active intervention and (2) participants experiencing no clinical improvements in depression severity or quality of life after using the sham app. Self-reported depression severity and quality of life were captured before and after using the sham app. A user satisfaction survey and semistructured interviews were conducted at the end of the study. Quantitative analyses included paired 2-tailed t tests. The semistructured interviews were conducted with 20 of the 21 participants, and these interviews were analyzed using rapid qualitative analysis. Results: Overall, 21 participants (meanage 42.0, SD 6.4 years; female: n=9, 43% and male: n=12, 57%) were enrolled. The average number of app log-ins was 17.8 (SD 10.6; range 1-41). There were 2 participants who only logged in 1 time, and 15 (71%) participants completed the goal of logging in an average of 3 times per week. No significant differences were found in depression severity (P=.50) or quality of life (quality of life: P=.42, physical health: P=.58, psychological health: P=.07, environmental health: P=.44, and social relationships: P=.86) after using the sham app. Of the 20 participants who completed the semistructured interview, 19 (95%) believed that they were using an active intervention. The user satisfaction survey revealed high overall satisfaction with the sham app with a score of 91%. Qualitative analyses revealed several recurring themes, including perceived value and impact, potential for behavior change, use patterns and engagement, perspective and usability, and perceptions of authenticity. Conclusions: Our sham app met our a priori criteria for suitability as a sham app. No clinical improvements from baseline were observed at the end of the study period, and all but 1 participant believed that they were using an active intervention. Demonstrating that this sham app is suitable as a control condition elevates the rigor of randomized clinical trials and ensures the efficacy of prescription digital therapeutics.

Indexed as

Mobile ApplicationsOpioid-Related DisordersPatient Acceptance of Health CareSmartphoneAdultFemaleHumansMaleMiddle AgedPatient SatisfactionQuality of Lifebelievabledigital healthplaceboprescription digital therapeuticsham software

Identifiers

PMID40779752
PMCPMC12334106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.